Antibody Response in Seropositive Multiple Sclerosis Patients Vaccinated with Attenuated Live Varicella Zoster Virus

Ross, Robert T.; Dawood, Nashwan; Cheang, Mary; Nicolle, Lindsay E.

doi:10.1155/1996/417061

Cited by 7 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only one study reported the absence of safety issues of the varicella-zoster vaccine administered in 50 treatment-naïve patients with progressive MS who were seropositive to varicella before vaccination. 32 However, the results are of limited value due to an insufficient description of the data in the manuscript.…”

Section: Results and Recommendationsmentioning

confidence: 97%

ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs

et al. 2023

View full text Add to dashboard Cite

Background: With the new highly active drugs available for people with multiple sclerosis (pwMS), vaccination becomes an essential part of the risk management strategy Objective: To develop a European evidence-based consensus for the vaccination strategy of pwMS who are candidates for disease-modifying therapies (DMTs). Methods: This work was conducted by a multidisciplinary working group using formal consensus methodology. Clinical questions (defined as population, interventions, and outcomes) considered all authorized DMTs and vaccines. A systematic literature search was conducted and quality of evidence was defined according to the Oxford Centre for Evidence-Based Medicine Levels of Evidence. The recommendations were formulated based on the quality of evidence and the risk–benefit balance. Results: Seven questions, encompassing vaccine safety, vaccine effectiveness, global vaccination strategy and vaccination in sub-populations (pediatric, pregnant women, elderly and international travelers) were considered. A narrative description of the evidence considering published studies, guidelines, and position statements is presented. A total of 53 recommendations were agreed by the working group after three rounds of consensus. Conclusion: This first European consensus on vaccination in pwMS proposes the best vaccination strategy according to current evidence and expert knowledge, with the goal of homogenizing the immunization practices in pwMS.

show abstract

Section: Results and Recommendationsmentioning

confidence: 97%

ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Only one study reported the absence of safety issues of the varicella‐zoster virus (VZV) vaccine administered in 50 treatment‐naïve patients with progressive MS who were seropositive to varicella before vaccination [32]. However, the results are of limited value due to insufficient description of the data in the manuscript.…”

Section: Results and Recommendationsmentioning

confidence: 99%

European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs

Otero‐Romero,

Lebrun‐Frénay,

Reyes

et al. 2023

Euro J of Neurology

View full text Add to dashboard Cite

Background and purpose: With the new highly active drugs available for people with multiple sclerosis (pwMS), vaccination becomes an essential part of the risk management strategy. We aimed to develop a European evidence-based consensus for the vaccination strategy of pwMS who are candidates for disease-modifying therapies (DMTs).Methods: This work was conducted by a multidisciplinary working group using formal consensus methodology. Clinical questions (defined as population, interventions and outcomes) considered all authorized DMTs and vaccines. A systematic literature search was conducted and quality of evidence was defined according to the Oxford Centre for Evidence-Based Medicine Levels of Evidence. The recommendations were formulated based on the quality of evidence and the risk-benefit balance.Results: Seven questions, encompassing vaccine safety, vaccine effectiveness, global vaccination strategy and vaccination in subpopulations (pediatric, pregnant women, elderly and international travelers) were considered. A narrative description of the evidence considering published studies, guidelines and position statements is presented. A total of 53 recommendations were agreed by the working group after three rounds of consensus. Conclusion:This first European consensus on vaccination in pwMS proposes the best vaccination strategy according to current evidence and expert knowledge, with the goal of homogenizing the immunization practices in pwMS.

show abstract

“…Patients receiving fi ngolimod can be advised to undergo vaccination against chickenpox because of the high risk of severe disease. Patients with exacerbations of MS are level of protective antibodies resulting from vaccination is independent of patients' ages, the stage of the main disease, and the level of disability [25].…”

Section: Vaccination Of Ms Patientsmentioning

confidence: 99%

Vaccination and Multiple Sclerosis – Current Situation

Boyко

Сиверцева

Чемакина

et al. 2022

Neurosci Behav Physi

View full text Add to dashboard Cite

Active immunization of patients with autoimmune diseases is a current challenge. Vaccination of patients with multiple sclerosis (MS) has been shown not to be associated with increased risk of exacerbation. A personalized approach to immunization of this group of patients is required, taking account of ongoing therapy and the nature of the course of illness. MS is not an absolute contraindication for vaccination against the new coronavirus infection. Vaccination can be with any of the currently authorized immunoformulations.

show abstract

Antibody Response in Seropositive Multiple Sclerosis Patients Vaccinated with Attenuated Live Varicella Zoster Virus

Abstract: It may be reasonable and safe to challenge the process of MS using large doses of the immunogenic proteins of the VZV to induce 'immune paralysis'.

Cited by 7 publications

References 20 publications

ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs

ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs

European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs

Vaccination and Multiple Sclerosis – Current Situation

Contact Info

Product

Resources

About